GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

111 papers

Active filtersClassification:Supporting

Showing 13-24 of total 111 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedSupporting evidence

Weight gain, adipose tissue remodeling and cardiometabolic disease in people with HIV.

Gorwood J; Capeau J; Béréziat V; Lagathu C

Jan 1, 2026

2026PubMedSupporting evidence

Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial.

Tuttle KR; Bjornstad P; Smith C; Pruijm M; McCown PJ; Hodgin JB; Cherney DZI; Belmar N; Chacko MM; Das V; Gunnarsson TP; Idorn T; Schytz PA; Zaratiegui A; Kretzler M

Jan 1, 2026Nature medicine

2026PubMedDirectly related

Interactions of Glucagon-Like Peptide-1 Receptor Agonists With GLP-1R-Gs Complex: Insights From Gaussian-Accelerated Molecular Dynamics.

Zhou X; Liu M; Shi Y; Duan X; Gao Y; Han W

Jan 1, 2026Proteins

2026PubMedSupporting evidence

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

Klein KR; Wysham C; Tuttle KR; Davies MJ; Cox D; Chen J; Wu WS; Denning M; Liu R; Ludwig L; Meskimen ER

Jan 1, 2026Lancet (London, England)

2026PubMedSupporting evidence

Melatonin and Diabetic Nephropathy: From Mechanistic Pathways to Translational Opportunities in Clinical Management.

Chapani MS; Ostadmohammadi K; Moulaei-Arani M; Sattari-Arani M; Panahi G; Moeini Taba SM; Sattari-Arani M

Jan 1, 2026Current medicinal chemistry

2026PubMedSupporting evidence

Racial and Ethnic Disparities in Medication Adherence Among Medicare Advantage Enrollees With Diabetes.

Essien UR; Roberts ET; Ruggiero DA; Tang JJ; Raghava S; Ayanian JZ; Tipirneni R

Jan 1, 2026JAMA network open

2026PubMedSupporting evidence

Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.

Amjad MM; Khan MM; Sarwar F; Ali A; Ali M; Bakhash F; Abid H; Ibrahim F; Mustafa K; Ali DE; Fayyaz MMN; Hassan H; Mian SM; Yaseen M; Qamar I; Khan AH; Ullah S; Khan BW

Jan 1, 2026Diabetes, obesity & metabolism

2026PubMedSupporting evidence

Beyond weight loss: a narrative review of tirzepatide's impact on muscle and lean mass in people with overweight and obesity.

Wilkinson T; Ramzan R

Jan 1, 2026Current medical research and opinion

2026PubMedSupporting evidence

Creatine for glucagon-like peptide-1-associated muscle loss.

Ostojic SM; Galyean S

Jan 1, 2026Clinical nutrition (Edinburgh, Scotland)

2026PubMedSupporting evidence

Pulsatile liraglutide on a biased tirzepatide background: a hypothesis.

Kopitovic I

Jan 1, 2026Frontiers in endocrinology

2026PubMedSupporting evidence

Potential Role of the Triple Receptor Agonist Retatrutide in Antipsychotic-Associated Metabolic Dysfunction Among Clozapine- and Olanzapine-Treated Schizophrenia Spectrum Disorders: A Narrative Review and Theoretical Framework.

Kaczynski MM; Zureikat RM; Kaczynski MR; Sitarz R; Karakuła-Juchnowicz H

Jan 1, 2026Biomedicines

2026PubMedSupporting evidence

The effectiveness of digital therapeutics in improving sleep quality: a systematic review and network meta-analysis.

Tong Z; Ye G; Fan S; Li Y; Zhang J; Zhang H; Chen Q; Wang H; Li H; Wang J

Jan 1, 2026BMC medicine